|
|
|
|
Healthcare Project Manager Resume
|
| Desired Industry: Healthcare |
SpiderID: 76187 |
| Desired Job Location: Richmond Hill, Georgia |
Date Posted: 9/17/2015 |
| Type of Position: Full-Time Permanent |
Availability Date: Immediately |
| Desired Wage: 80000 |
|
|
U.S. Work Authorization: Yes |
| Job Level: Management (Manager, Director) |
Willing to Travel: Yes, 25-50% |
| Highest Degree Attained: Bachelors |
Willing to Relocate: No |
Objective:
Dynamic and highly analytical professional
with broad-based experience in directing
all aspects of health care encompassing,
medical coding, revenue cycle management,
and clinical research center management.
Experience:
RTR Medical Group ~ Savannah, GA
Director of Operations and Clinical
Research Director 2001-Present
Spearhead all aspects of a multi-
physician medical practice and office
logistics as well as ancillary
facilities as part of a telecommute
position in a matrix office environment
Comply with matrix organizational
strategy through optimal allocation of
resources and demonstration of ROI
including financial objectives,
forecasting, budget preparation, and
expenditure planning and execution with
routine EVM variance analysis in
directing several projects
Maximize effective communication and
leadership between project teams in the
aspects of project life cycle, risk
management, and course correction
implementation
Perform reimbursement contract
negotiation for physician practice and
ancillary facilities including ASC, APC,
DRG, RUGII, fee schedules, and AWP; as
well as Medicare advantage
plans and private insurance plans
Maintain strict compliance with state
and corporate regulatory policies and
procedures such as Health Insurance
Portability and Accountability Act
(HIPAA), Clinical Laboratory
Improvement Amendments (CLIA), Joint
Commission on Accreditation of
Healthcare JCAHO, and Occupational
Safety and Health Administration (OSHA)
into daily office practices
Work closely with financial accountants
and advisors regarding corporate
accounts payable, reconciliation, and
balanced financial corporate accounts
Effectively handle RBRVS and RVU
tracking system for physician
performance within the clinical setting
Document and arrange data from various
sources including SQL databases, Excel
files, and Microsoft Reporting Services
(SSRS) environment to maintain automated
reporting services
Generate standard budget, forecast,
trend, audit, and control reports by
collecting information from various
departments
Preside over staff training regarding
ICH-GCP guidelines, ICF process, SAE
reporting, and protocol specific
requirements
Adhere to established protocols in
completing eCRF and paper CRF as well as
with labeling and shipping according to
IATA guidelines
Administer project management with Agile
and Waterfall models
Notable Accomplishments:
Maximized revenue and high-standard
patient care by acknowledging the value
of utilizing specialized treatments
Earned reputation for sustaining the
medical group’s accreditation in NCQA
from 2012 until now
Boosted productivity by facilitating
employee meeting and performance
evaluation as well as managing the
Billing Department, front office, and
medical staff consisting of 35
employees
Leveraged industry expertise in Clinical
Research Center management by leading
all aspects of clinical trials with
$500K project budget and $1M project
annual revenue
Successfully executed EHR system that
provided reporting for HEDIS measures
and CMS star measure ratings along with
RAF reporting with practice physicians
measuring patients’
health status
Developed patient, physician, and
employee scheduling which resulted to
the increase in profits and accounts
receivable
Earlier Career
Orthopedic Center of Savannah ~
Savannah, GA
Patient Finance Director and Consultant
2000-2001
Metropolitan Hospital ~ Grand Rapids, MI
Registered Nurse, Medical-Surgical
Emergency Room 1999-2001
Spectrum Health ~ Grand Rapids, MI
Licensed Practical Nurse (LPN),
Registered Nurse (RN), and
Electrocardiogram Technician
OB/GYN, PEDS ICU, and Level 1 Trauma
1993-1999
Education:
Bachelor of Science in Healthcare
Administration ~ University of Michigan
~ Ann Arbor, MI
Bachelor of Science in Nursing
(Registered Nurse) ~ Grand Valley State
University ~ Allendale, MI
Associate Degree in Nursing (Licensed
Practical Nurse) ~ Grand Rapids
Community College, Grand Rapids, MI
Affiliations:
Professional Affiliations
Society of Clinical Research Associates
(SOCRA), Member
American Academy of Dermatology,
Melanoma Monday Sponsor
Skills:
Project Management ~ Regulatory
Compliance ~ Quality Assurance ~ Profit
Maximization ~ Healthcare Operations
Budget and Finance ~ Cross-functional
Collaboration ~ Continuous Process
Improvement ~ Training and Leadership
Strategic Planning and Implementation ~
Risk Assessment and Mitigation ~
Business Development ~ Lean Process Cost
Reduction ~ Matrix Environment
Management ~ Business Process Analysis
Additional Information:
Certifications
Six Sigma Champion Certified (SSCC):
2015 ~ Management and Strategy Institute
~ Downingtown, PA
Six Sigma Lean Green Belt in Healthcare
(LGBH): 2015 ~ Management and Strategy
Institute ~ Downingtown, PA
Project Management - Lean Process
Certified (PM-LPC): 2015
Management and Strategy Institute ~
Downingtown, PA
Professional Development
IATA Training, Mayo Medical Laboratories
(In Progress)
Shipment of Infections Substances and
Dry Ice, Materials Covered for Division
6.2 and Class 9
CITI GCP Training (In progress)
Bracket Neuropsychological Scales
Training by Dr. David Miller (In
progress)
(MMSE, ADAS-Cog, NPS, CSDD, Qol-AD, NPI,
NPI-C, ADCS-ADL, CSDD, RUD-Lite, C-SSRS,
CDR-Sb, ADCS-CGIC, ISLT, and Modified
Hacinski Ischemic Scale)
Clinical Trials and Research
Jan 2015-Present
Eisai E2609-G000-202: A Placebo-
Controlled, Double-Blind, Parallel-
Group, Randomized, Proof-of-Concept,
Dose-Finding Study to Evaluate Safety,
Tolerability, and Efficacy of
E2609 in Subjects with Mild Cognitive
Impairment Due to Alzheimer's Disease
(Prodromal Alzheimer's Disease) and Mild
to Moderate Dementia Due to Alzheimer's
Disease
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Biogen
Sponsor: Eisai Inc.
Main Function/Objective: A Phase 2 study
to evaluate safety and efficacy in
participants with mild cognitive
impairment due to Alzheimer's
disease/prodromal Alzheimer's disease
(referred to as MCI/Prodromal) and mild
to moderate dementia due to Alzheimer's
disease (referred to as mild to moderate
AD).
Feb 2014-Present
AstraZeneca D5896C00027: A 26-Week,
Randomized, Double-blind, Parallel-
group, Active Controlled, Multicenter,
Multinational Safety Study Evaluating
the Risk of Serious Asthma-
related Events During Treatment With
Symbicort', a Fixed Combination of
Inhaled Corticosteroid (ICS)
(Budesonide) and a Long Acting B2-
agonist (LABA) (Formoterol) as Compared
to
Treatment With ICS (Budesonide) Alone in
Adult and Adolescent (>12 Years of Age)
Patients with Asthma
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): AstraZeneca
Sponsor: AstraZeneca
Main Function/Objective: Evaluation of
the safety of Symbicort compared to
inhaled corticosteroid alone during 6
months in adult and adolescent patients
with asthma.
Feb 2014-Present
AstraZeneca D513BC00001: A
Multinational, Randomized, Double-Blind,
Placebo-Controlled Trial to Evaluate the
Effect of Ticagrelor Twice Daily on the
Incidence of Cardiovascular
Death, Myocardial Infarction or Stroke
in Patients with Type 2 Diabetes
Mellitus (THEMIS - Effect of Ticagrelor
on Health Outcomes in Diabetes Mellitus
Patients Intervention
Study)
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): AstraZeneca
Sponsor: AstraZeneca
Main Function/Objective: Comparison of
the effect of ticagrelor versus placebo
in patients with Type 2 Diabetes
Mellitus.
Nov 2013-Present
Merck Sharp and Dohme Corporation MK-
8835-004: Randomized, Double-Blind,
Placebo-Controlled, Parallel Group Study
to Assess Cardiovascular Outcomes
Following Treatment With
Ertugliflozin (MK-8835/PF-04971729) in
Subjects with Type 2 Diabetes Mellitus
and Established Vascular Disease
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Pfizer
Sponsor: Merck Sharp and Dohme
Corporation
Main Function/Objective: A study of the
cardiovascular outcomes following
treatment with ertugliflozin in
participants with type 2 diabetes
mellitus (T2DM) and established
vascular disease. The main objective of
this study is to assess the
cardiovascular safety of ertugliflozin.
This trial includes a pre-defined
glycemic sub-study in participants
receiving background insulin with or
without metformin and another pre-
defined glycemic sub-study in
participants receiving background
sulfonylurea monotherapy.
Nov 2013-Present
Merck Sharp and Dohme Corp MK-8835-007:
A Phase 3, Randomized, Double-Blind,
Placebo-Controlled, 26-Week Multicenter
Study with a 78-Week Extension to
Evaluate the Efficacy and
Safety of Ertugliflozin in Subjects with
Type 2 Diabetes Mellitus and Inadequate
Glycemic Control on Metformin
Monotherapy.
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Pfizer
Sponsor: Merck Sharp and Dohme
Corporation
Main Function/Objective: An efficacy and
safety study of ertugliflozin in
participants with type 2 diabetes
mellitus and inadequate glycemic control
on metformin monotherapy.
The primary study hypothesis is that at
week 26, the mean reduction from
baseline in hemoglobin A1c (HbA1c) for
ertugliflozin is greater than that for
placebo.
Nov 2013-Present
Instituto Grifols, S.A. IG1002 (UBC): A
Multicenter, Randomized, Controlled
Study to Evaluate the Efficacy and
Safety of Short-Term Plasma Exchange
Followed by Long-Term
Plasmapheresis With Infusion of Human
Albumin Combined with Intravenous
Immunoglobulin in Patients with Mild-
Moderate AD
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Grifols Biologicals
Inc.
Sponsor: Instituto Grifols, S.A.
Main Function/Objective: Evaluation of
the changes in cognitive, functional,
behavioral and global domains based on
the different applicable psychometric
batteries and scales.
Oct 2013-Present
Forest Pharmaceuticals LAS-MD-45:
Double-blind, Randomized, Placebo-
controlled, Parallel-group, Phase IV
Study to Evaluate the Effect of
Aclidinium Bromide on Long-term
Cardiovascular Safety and COPD
Exacerbations in Patients with Moderate
to Very Severe COPD (ASCENT COPD)
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Forest Laboratories
Sponsor: Forest Laboratories
Main Function/Objective: Evaluation of
the effect of Aclidinium bromide on the
cardiovascular safety and COPD
exacerbations in patients with moderate
to very severe COPD, as
defined by the Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
criteria (GOLD, 2011). The objectives of
this study are to assess the safety of
Aclidinium bromide
on major adverse cardiovascular events
(MACE), to assess the overall safety of
Aclidinium bromide and to assess whether
Aclidinium bromide reduces moderate or
severe COPD
exacerbations.
May 2013-Dec 2013
Novartis Pharmaceuticals CENA713D2406
(PPD): Multicenter prospective
observational study to assess resource
utilization and health-related quality
of life in patients with
Alzheimer’s Disease receiving Exelon
Patch
Role: Clinical Trial Director / Project
Manager
Collaborator(s): Novartis
Pharmaceuticals
Sponsor: Novartis Pharmaceuticals
Main Function/Objective: An
observational study to assess resource
utilization and health-related quality
of life in patients with Alzheimer’s
Disease receiving Exelon' Patch
Jan 2013-Present
Elan Pharmaceuticals ELND005-AG251
(PPD): A 36-Week Safety Extension Study
of Oral ELND005 for Treatment of
Agitation and Aggression in Patients
with Moderate to Severe
Alzheimer's Disease.
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Elan Pharmaceuticals
Sponsor: Transition Therapeutics Ireland
Limited
Main Function/Objective: Evaluation of
the safety and tolerability of ELND005
treatment with up to 48 weeks of
exposure, in moderate to severe AD
patients with agitation and
aggression.
Nov 2012-Present
Elan Pharmaceuticals ELND005-AG201(PPD):
A Prospective, Randomized, Double-Blind,
Placebo-Controlled, Phase 2 Efficacy and
Safety Study of Oral ELND005 for
Treatment of
Agitation and Aggression in Patients
with Moderate to Severe Alzheimer's
Disease
Role: Clinical Trial Director and Sub-
Investigator
Collaborator(s): Elan Pharmaceuticals
Sponsor: Transition Therapeutics Ireland
Limited
Main Function/Objective: Determine
whether ELND005 is effective in treating
symptoms of agitation and aggression in
patients with Alzheimer's disease.
Jul 2012-Present
Forest Research Institute NAC-MD-01: A
Multicenter, Randomized, Double-blind,
Placebo-Controlled, 8-Week Study to
Evaluate the Safety and Efficacy of
Nebivolol and Valsartan
Given as a Fixed Dose Combination in
Patients with Stage 1 or 2 Essential
Hypertension
Reference:
Available upon request.
Candidate Contact Information:
JobSpider.com has chosen not to make contact information available on this page.
Click "Contact Candidate" to send this candidate a response. |
|
|
|
|
|